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To the Editor:
With the discovery of germ-line mutations in the mis-
match-repair genes, genetic testing for hereditary non-
polyposis colorectal cancer (HNPCC) has become a re-
ality. However, concern about potential genetic
discrimination, with regard to insurance and employ-
ment, has surfaced among affected individuals and
health-care providers. Owing to the lack of information
regarding insurance providers’ attitudes toward both
HNPCC individuals diagnosed with cancer and asymp-
tomatic gene carriers, we decided to assess the insurance-
industry attitude regarding the offering of health, life,
and disability insurance to HNPCC gene carriers and
at-risk family members.
An anonymous survey with 14 questions, which in-
cluded a self-addressed, stamped envelope, was mailed
to 1,000 health, life, and disability insurance company
presidents. An insurance company database consisting
of 5,178 companies was purchased from NAIC Data-
base products. Twenty companies, from each state, that
were reported to sell health, life, and disability insurance
were chosen randomly from the purchased database. An
introductory letter defining HNPCC and the anonymous
nature of the study accompanied each mailed question-
naire. Only one mailing was sent. A gene carrier was
defined as someone with a germ-line mutation in one of
the genes responsible for HNPCC. An at-risk family
member was defined as someone who had a 50% chance
of carrying the mutation for the defective gene.
Of the 1,000 surveys mailed, 4 were not delivered and
79 were returned. Two of the returned surveys were
excluded, since they were mailed to different locations
of the same company. There were 77 (7.7%) responses
to the mailing. Five surveys were returned unanswered,
and 6 were returned labeled “not applicable.” Even
though we did not know the size of the companies that
responded to our survey, we estimated, on the basis of
our response rate, that our respondents probably issue
!5% of the insurance policies sold in the United States.
The survey consisted of three sections, with six ques-
tions on health insurance, four questions on life insur-
ance, and four questions on disability insurance. A total
of 66 usable questionnaires were returned, but not all
were completed for all three types of insurance: Re-
sponses were as follows: 49/66 responded as health in-
surance providers, 46/66 as life insurance providers, and
30/66 as disability insurance providers. These 66 ques-
tionnaires served as the basis for this report.
With regard to health insurance, 48 (98%) insurance
providers responded that they would insure at-risk fam-
ily members, whereas 1 (2%) insurer would not. Three
of the 48 insurers would provide the insurance, with the
following conditions: a higher premium (1); if the in-
sured “does not carry a bad gene” (1); and depending
on a guarantee (1). Forty-four (90%) of the insurers
would provide insurance to a gene carrier. Those who
would not provide the insurance had the following rea-
sons: no explanation (1); not unless state mandated (1);
cost of surveillance and treatment too high (1); would
offer colorectal cancer rider (1); and depends on guar-
antee (1).
Thirty-seven (76%) providers would not increase the
premium for an at-risk member. However, 9 (18%) pro-
viders would increase the premium for an at-risk mem-
ber, whereas 2 providers were not sure whether the pre-
mium would be increased. One company answered that
it would not increase the premium but would consider
inserting an exclusion rider. With regard to health in-
surance for gene carriers, 38 (78%) providers would not
increase the premium, 10 (20%) providers would, and
1 (2%) provider was not sure.
Tables 1 and 2 indicate the responses to the questions
regarding (1) payment for colonoscopy at more-frequent
intervals for HNPCC at-risk individuals than for the
general population and (2) payment for prophylactic ab-
dominal colectomy and ileorectal anastomosis for an
HNPCC gene carrier. It can be seen that the majority
(61%) of the health insurance providers would pay for
more-frequent colonoscopies and that 35% of the in-
surers would pay for prophylactic surgery for a gene
carrier.
With regard to life insurance, 32 (70%) companies
would sell life insurance to at-risk individuals, 2 (4%)
would not, and 12 (26%) would sell it at a higher pre-
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Table 2
Health Insurance Providers’ Willingness to Pay
for Prophylactic Surgery for an HNPCC Gene
Carrier
No. (%) of Providers
Yes 17 (35)a
No 22 (45)b
a Three providers responded that payment
would be made if medical necessity had been es-
tablished, one that payment would be made if
there was no rider, and one that payment would
be made if medical necessity had been established
and if the procedure was not experimental.
b One provider responded that payment would
not be made unless the procedure was standard
care, one responded that payment was subject to
review of each case, and one responded that pay-
ment normally is not made for preventive surgery.
Table 3
Access to DNA Test Results, by Type of Insurance Provider
Access to DNA
Test Results
No. (%) of Life Insur-
ance Providers
No. (%) of Disability
Insurance Providers
Yes 26 (57)a 20 (67)
No 14 (30) 8 (30)
Not applicable 2 (4) 1 (3)
Do not know 1 (2) 1 (3)
Maybe 1 (2) )
No answer 2 (4) )
a One provider stated that they would have access to test results but
would decline to insure for economic reasons.
mium. Thirty-two (70%) of the respondents would sell
life insurance to gene carriers, whereas 2 (4%) would
not, 10 (22%) would sell it at a higher premium, 1 (2%)
was not sure, and 1 (2%) did not answer the question.
Forty-three (93%) of the life insurance providers did not
require genetic testing prior to insuring a member of an
HNPCC kindred. One company did require genetic
testing. Two companies would require genetic testing
prior to selling life insurance if the coverage was
1$50,000–$100,000 or 1$350,000, respectively.
With regard to disability insurance, 24 (80%) com-
panies would sell disability insurance to at-risk individ-
uals, 1 (3%) would not, and 5 (17%) would sell it at a
higher premium. Gene carriers would be insured by 23
(77%) companies. Three (10%) companies would not
sell disability insurance to gene carriers, whereas 4
(13%) would charge a higher premium.
Twenty nine (97%) of the disability insurance pro-
viders did not require genetic testing prior to insuring a
member of an HNPCC kindred. One company did re-
quire genetic testing. As shown in table 3, the majority
of the life and disability insurance providers would be
allowed access to DNA test results.
In the interpretation of our results, there are several
factors that should be kept in mind. Even though our
survey was completely anonymous, only 79 (7.9%) of
the surveys were returned. This is a limitation of our
data set. This could have been improved if we had sent
additional mailings. However, because of the anonymity
of the survey, the logistics of remailing 1,000 question-
naires was insurmountable, and, hence, the decision was
made to mail the survey only once. There were several
potential reasons for the poor response rate. Among
them was that the survey may have been mailed to an
inappropriate insurance company executive, which
could have led to fear of identification and of adverse
public relations for the company or fear that the com-
pany could be held accountable, in the future, for any
answers provided. Importantly, we do not claim that the
results reflect the whole insurance industry. However,
they at least provide some information about insurance-
provider attitudes toward HNPCC gene carriers and at-
risk individuals.
Even though we had a limited response (7.7%) to the
questionnaires and the survey respondents probably is-
sue !5% of the insurance policies sold in the United
States, our results indicate that the majority of health,
life, and disability insurance providers with an opinion
would be willing to sell insurance to both HNPCC gene
carriers and at-risk individuals. Nevertheless, there were
some that would not insure these individuals. The in-
terpretation of our results indicates that there is probably
a minority of insurance providers that potentially will
discriminate against HNPCC gene carriers and at-risk
individuals. It is the latter insurance providers who need
to be educated about the condition and the benefits of
surveillance and early detection.
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